Health Care·Pharmaceuticals·$277.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.27 | N/A | +5.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.27 | N/A | +5.57% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Overall, management expressed a cautious outlook amid market pressures. They reiterated their commitment to advancing their product pipeline.
Management highlighted ongoing challenges in the market.
They emphasized a focus on innovation and pipeline development.
Novartis reported earnings that exceeded expectations on EPS, but the stock fell by 2.27% following the report. The decline may reflect investor concerns about the lack of revenue details and overall market conditions. Without updated guidance, investors may remain cautious about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Jul 20, 2015